US EditionRoche Pharmaceuticals launches $282 million biologics plant in Shanghai
Summary by Ecns
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Roche Invests $300M in New Vabysmo Production Plant in China
Roche is making a significant investment of around 2.04 billion Chinese yuan (approximately $282 million) to construct a new biomanufacturing plant in Shanghai, China, aimed at bolstering the production of its eye medication Vabysmo, known locally as Luoshijia. The facility will be Roche’s second for branded medicines in China and is set to occupy 25,000 square meters in Shanghai’s Zhangjiang High-tech Park. Scheduled for completion in 2029, the…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
